Neal D. Shore, MD, FACS

Neal Shore, MD, FACS, discusses sasanlimab and its potential impact for community oncologists when treating patients with high-risk non–muscle invasive bladder cancer.

Neal Shore, MD, FACS, discusses a study aimed to investigate the real-world survival outcomes of men with metastatic castration-sensitive prostate cancer treated with either apalutamide or enzalutamide in the United States.

Neal Shore, MD, discusses the long-term exposure analysis of darolutamide in the phase 3 ARAMIS Rollover trial for patients with nonmetastatic castration-resistant prostate cancer.

Neal Shore, MD, FACS, discusses the purpose behind investigating enzalutamide in a cohort of patients with metastatic hormone-sensitive prostate cancer who were previously treated with local therapy as a post-hoc analysis of the ARCHES study.

Neal Shore, MD, FACS discusses results from a post-hoc analysis of the phase 3 ARCHES trial.

Neal Shore, MD, FACS, explains the relationship between the use of darolutamide and control of urinary and bowel adverse events, as observed in an analysis of the phase 3 ARAMIS clinical trial.

Neal Shore, MD, discusses the current outlook for the treatment landscape in advanced or metastatic urothelial carcinoma.

Neal D. Shore, MD, FACS, discusses the current treatment landscape and upcoming drugs being reviewed by the FDA for the treatment of patients with bladder cancer.

Neal D. Shore, MD, FACS, discusses the results of the retrospective review on real-world patterns of genomic testing in patients with metastatic castration-resistant prostate cancer.

Neal Shore, MD, medical director of Carolina Urologic Research Center, discusses corticosteroid-associated adverse events with low-dose prednisone given with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC).

Neal D. Shore, MD, FACS, Atlantic Urology Clinics, discusses glypican-1 as a biomarker for prostate cancer.

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, on the utility of the androgen receptor inhibitor ODM-201 for the treatment of castration-resistant prostate cancer (CRPC).

Neal D. Shore, MD, FACS, discusses patient considerations following treatment with radium-223 for bone metastases from prostate cancer.